Un estudio para explorar la eficacia de JNJ-89495120 en el tratamiento del trastorno depresivo mayor (Moonlight-1)
Un estudio de prueba de concepto aleatorizado, doble ciego, multicéntrico, controlado con placebo para evaluar la eficacia, seguridad y tolerabilidad de JNJ-89495120 como monoterapia en participantes adultos con trastorno depresivo mayor (TDM)
The purpose of this study is to evaluate how well JNJ-89495120 works (anti-depressant effects) and how well it is tolerated as compared to placebo on reducing the symptoms of depression in participants with major depressive disorder (MDD).
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Tipo de estudio
Tipo de estudio
Inscripción (Actual)
Inscripción
Fase
Fase
- Fase 2
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Alabama
-
Huntsville, Alabama, Estados Unidos, 35801
- UAB Huntsville Regional Medical Campus
-
-
Arizona
-
Chandler, Arizona, Estados Unidos, 85224
- Chandler Clinical Trials
-
Phoenix, Arizona, Estados Unidos, 85012
- IMA Clinical Research PC Phoenix
-
Tucson, Arizona, Estados Unidos, 85724
- University of Arizona
-
Tucson, Arizona, Estados Unidos, 85704
- Noble Clinical Research
-
-
California
-
Bellflower, California, Estados Unidos, 90706
- CI Trials
-
Encino, California, Estados Unidos, 91316
- Wake Research PRI Encino
-
Garden Grove, California, Estados Unidos, 92844
- National Institute Of Clinical Research
-
Newport Beach, California, Estados Unidos, 92660
- WR-Newport Beach
-
Orange, California, Estados Unidos, 92866
- ATP Clinical Research
-
Redlands, California, Estados Unidos, 92374
- Anderson Clinical Research
-
San Diego, California, Estados Unidos, 92103
- Artemis Institute for Clinical Research
-
San Jose, California, Estados Unidos, 95124
- Lumos Clinical Research Center LLC
-
Santa Ana, California, Estados Unidos, 92705
- Syrentis Clinical Research
-
Temecula, California, Estados Unidos, 92591
- Inland Psychiatric Medical Group Inc
-
Walnut Creek, California, Estados Unidos, 94596
- Sunwise Clinical Research
-
-
Colorado
-
Denver, Colorado, Estados Unidos, 80209
- Mountain View Clinical Research
-
-
Florida
-
Fort Myers, Florida, Estados Unidos, 33912
- Gulfcoast Medical Research Center
-
Hollywood, Florida, Estados Unidos, 33021
- The Medici Medical Research
-
Homestead, Florida, Estados Unidos, 33030
- Advanced Research Institute of Miami
-
Maitland, Florida, Estados Unidos, 32751
- K2 Medical Research
-
Miami, Florida, Estados Unidos, 33126
- Pharmax Research Clinic Inc
-
Miami, Florida, Estados Unidos, 33135
- Wellness Research Center
-
Pembroke Pines, Florida, Estados Unidos, 33024
- Best Choice Medical and Research Service
-
Tampa, Florida, Estados Unidos, 33629
- Interventional Psychiatry of Tampa Bay
-
West Palm Beach, Florida, Estados Unidos, 33407
- Health Synergy Clinical Research
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30328
- Synexus Clinical Research US Inc
-
Decatur, Georgia, Estados Unidos, 30030
- iResearch Atlanta LLC
-
Snellville, Georgia, Estados Unidos, 30078
- Accelerated Clinical Research Group LLC
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60637
- University of Chicago Medical Center
-
-
Indiana
-
Indianapolis, Indiana, Estados Unidos, 46202
- Indiana University IU Health
-
-
Louisiana
-
New Orleans, Louisiana, Estados Unidos, 70115
- DelRicht Research
-
-
Maryland
-
Gaithersburg, Maryland, Estados Unidos, 20877
- CBH Health
-
-
Massachusetts
-
Worcester, Massachusetts, Estados Unidos, 01655
- University of Massachusetts Medical School
-
-
New York
-
Brooklyn, New York, Estados Unidos, 11229
- Integrative Clinical Trials LLC
-
-
Ohio
-
Cincinnati, Ohio, Estados Unidos, 45219
- University of Cincinnati
-
Cincinnati, Ohio, Estados Unidos, 45215
- Patient Priority Clinical Sites LLC
-
Columbus, Ohio, Estados Unidos, 43210
- OSU Department of Psychiatry and Behavioral Health
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Estados Unidos, 73116
- Paradigm Research Professionals, LLC
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Estados Unidos, 19104
- University of Pennsylvania
-
-
South Carolina
-
North Charleston, South Carolina, Estados Unidos, 29405
- Coastal Carolina Research Center
-
-
Texas
-
McKinney, Texas, Estados Unidos, 75071
- Revival Research Institute LLC
-
-
Utah
-
Clinton, Utah, Estados Unidos, 84015
- Alpine Research Organization
-
-
Washington
-
Everett, Washington, Estados Unidos, 98201
- Core Clinical Research
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Primary psychiatric diagnosis of recurrent major depressive disorder, without psychotic features, based on clinical assessment using diagnostic and statistical manual of mental disorders (DSM)-5 criteria and confirmed with the mini international neuropsychiatric interview (MINI)
- Participant had to have at least one previous major depressive disorder (MDD) episode prior to their current episode
- Were first diagnosed with depression before the age of 55
- Are in a current episode of depression: Episode length must be at least 2 months but not longer than 24 months
- Have taken 0, 1, or 2 treatments for depression in your current episode
- Body mass index (BMI) within the range 18 to 35 kilograms per square meter (kg/m^2) at screening
Exclusion Criteria:
- Treatment with vagus nerve stimulation (VNS), electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), deep brain stimulation (DBS), or ketamine/esketamine within the current or past major depressive episodes
- Current or past DSM-5 diagnosis of bipolar disorder, psychotic disorders, borderline personality disorder, antisocial personality disorder, or current obsessive-compulsive disorder
- Post-traumatic stress disorder within the past three years of screening
- Dementia, any dementing disease, intellectual disability, or neurocognitive disorder
- History of Alcohol and Substance use disorders within 6 months of screening, with the exclusion of nicotine, caffeine, and mild cannabis use disorder, according to the MINI and Clinical Assessment
- Known allergies, hypersensitivity, or intolerance to JNJ-89495120 or its excipients
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Doble
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Experimental: Arm 1: JNJ-89495120 Dose A
Participants will receive JNJ-89495120 dose A during the double-blind (DB) treatment phase in Period 1 and Period 2 of the study. |
JNJ-89495120 will be administered. |
|
Experimental: Arm 2: JNJ-89495120 Dose A and Dose B
Participants will receive JNJ-89495120 dose A in Period 1 followed by JNJ-89495120 dose B in Period 2 during the DB treatment phase of the study. |
JNJ-89495120 will be administered. |
|
Comparador de placebos: Arm 3: Placebo Group
Participants will receive placebo matched to JNJ-89495120 during the DB treatment phase in Period 1 and Period 2 of the study. |
Placebo will be administered. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change from Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score to Day 5
Periodo de tiempo: Baseline up to Day 5
|
The MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The scale consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score of 60. Higher scores represent a more severe condition. |
Baseline up to Day 5
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change from Baseline in MADRS Total Score to Day 2
Periodo de tiempo: Baseline up to Day 2
|
The MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The scale consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score of 60. Higher scores represent a more severe condition. |
Baseline up to Day 2
|
|
Change from Baseline in Clinician Global Impression-Severity (CGI-S) Scale Score to Days 2 and 5
Periodo de tiempo: Baseline up to Day 2 and Day 5
|
The CGI-S provides an overall clinician-determined summary measure of the severity of the participant's illness. The CGI-S evaluates the severity of psychopathology on a scale of 1 to 7. Participant is assessed on severity of illness at the time of rating according to: 1=normal (not at all ill); 2=borderline ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill participants. Higher score indicating greater severity. |
Baseline up to Day 2 and Day 5
|
|
Change from Baseline in Symptoms of Major Depressive Disorder Scale (SMDDS) Total Score to Day 5
Periodo de tiempo: Baseline up to Day 5
|
The SMDDS is a 16-item patient reported outcome (PRO) measure. Each item is rated by the participant according to a 5-point Likert scale, where 0 denotes "Not at all" or "Never" and 4 denotes "Extremely" or "Always". Before summing the items to create a total score, item 11 and item 12 are combined into a single score by selecting the highest severity on either item. The total score is then created by summing the responses on the 15 items, which range from 0 to 60. Higher score indicates more severe depressive symptomatology. |
Baseline up to Day 5
|
|
Change from Baseline in Generalized Anxiety Disorder-7 (GAD-7) Scale Score to Day 5
Periodo de tiempo: Baseline up to Day 5
|
The GAD-7 scale is a self-administered questionnaire designed to measure anxiety. GAD-7 has seven items, which measure frequency of various signs of GAD using a 4-point Likert scale (where, Not at all = 0, Several days = 1, More than half the days = 2, and Nearly every day = 3). The total score ranges from 0 to 21 with increasing scores indicative of greater severity of symptoms of anxiety. Severity of anxiety on the GAD-7 is rated as follows: none (0-4), mild (5-9), moderate (10-14) and severe (15-21). |
Baseline up to Day 5
|
|
Number of Participants with Adverse Events (AEs)
Periodo de tiempo: Up to approximately 18 weeks
|
An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. |
Up to approximately 18 weeks
|
|
Number of Participants with Abnormalities in Vital Signs Parameters
Periodo de tiempo: Up to approximately 18 weeks
|
Participants with abnormalities in vital signs (supine blood pressure, pulse/heart rate, respiratory rate, oral temperature) parameters will be reported. |
Up to approximately 18 weeks
|
|
Number of Participants with 12-Lead Electrocardiogram (ECG) Abnormalities
Periodo de tiempo: Up to approximately 18 weeks
|
Participants with 12-lead ECG abnormalities will be reported. |
Up to approximately 18 weeks
|
|
Number of Participants With Abnormalities in Laboratory Parameters
Periodo de tiempo: Up to approximately 18 weeks
|
Participants with abnormalities in clinical laboratory parameters (hematology and serum chemistry) will be reported. |
Up to approximately 18 weeks
|
|
Number of Participants Reporting Changes in Weight/Body Mass Index (BMI)
Periodo de tiempo: Up to approximately 18 weeks
|
Participants with changes in weight/BMI will be reported. |
Up to approximately 18 weeks
|
|
Suicidal Ideation Assessment Using Columbia Suicide Severity Rating Scale (C-SSRS) Score
Periodo de tiempo: Up to approximately 18 weeks
|
The C-SSRS scale consists of 28 items in 4 sections: suicide behavior, actual attempts, suicidal ideation, and intensity of ideation. Suicidal ideation consists of 5 'yes/no' items: wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with any methods (not plan) without intention to act, active suicidal ideation with some intent to act without specific plan, active suicidal ideation with specific plan and intent. Only items with yes responses are listed. Worsening of suicidal ideation was an increase in severity of suicidal ideation from baseline. |
Up to approximately 18 weeks
|
|
Change from Baseline in Cognitive Functioning Measured by the Hopkins Verbal Learning Test-Revised (HVLT-R)
Periodo de tiempo: From Baseline up to 4 weeks
|
The HVLT-R, a measure of verbal learning and memory, is a 12-item word list recall test. Administration includes 3 learning trials, a delayed recall (20-minute) trial, and a 24-word recognition list (including 12 target and 12 foil words). The test administrator reads instructions and word lists aloud, and records words recalled/recognized by the participant. Three learning trials are combined to calculate a total recall score learning, delayed recall, and recognition trials. |
From Baseline up to 4 weeks
|
|
Change from Baseline in Cognitive Functioning Measured by the Digit Symbol Substitution Test (DSST)
Periodo de tiempo: From Baseline up to 4 weeks
|
The DSST is recognized as covering all of the cognitive performance aspects: speed of processing, executive functioning, and attention. The DSST measures attention, working memory, sustained visual attention and psychomotor speed. Participants are given a table that pairs digits and symbols, and asked to decipher a code using the table, completing as many as possible in 90 seconds. |
From Baseline up to 4 weeks
|
|
Plasma Concentrations of JNJ-89495120
Periodo de tiempo: Pre-dose (0 hours), and Post-dose on Days 1, 5 and 13
|
Plasma concentrations of JNJ-89495120 will be reported. |
Pre-dose (0 hours), and Post-dose on Days 1, 5 and 13
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Investigadores
Investigadores
- Director de estudio: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Inicio del estudio
Finalización primaria (Actual)
Finalización primaria
Finalización del estudio (Actual)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
Otros números de identificación del estudio
- 89495120MDD2001
- 89495120MDD2001 (Otro identificador: Janssen Research & Development, LLC)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
The data sharing policy of Johnson & Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .